secwatch / observer
8-K filed February 8, 2024, 6:59 PM ET ticker PDEX CIK 0000788920
earnings confidence high sentiment negative materiality 0.60

Pro-Dex Q2 sales up 12% to $12.6M but net income falls to $500K on investment losses; new buyback launched

PRO DEX INC

2024-Q2 EPS reported -$0.03 revenue$24,526,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PRO DEX INC reported six months ended December 31, 2023 results: revenue $24.5 million, net income Net loss for the six months ended December 31, 2023, was $115,000, EPS $0.03 per diluted share.

Period
six months ended December 31, 2023
Revenue
$24.5 million
Net income
Net loss for the six months ended December 31, 2023, was $115,000
EPS
$0.03 per diluted share
Result
reported results
Exact text from the filing
fair value, and the valuation can be highly volatile. Six Months Ended December 31, 2023 Net sales for the six months ended December 31, 2023, increased $2.2 million, or 10%, to $24.5 million from $22.4 million for the six mo nths ended December 31, 2022, due primarily to increased repair revenue from the orthopedic surgical handpiece that we sell to our
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PRO DEX INC reported fiscal 2024 second quarter ended December 31, 2023 results: revenue $12.6 million, net income $500,000, EPS $0.14 per diluted share.

Period
fiscal 2024 second quarter ended December 31, 2023
Revenue
$12.6 million
Net income
$500,000
EPS
$0.14 per diluted share
Result
reported results
Exact text from the filing
Net sales for the three months ended December 31, 2023, increased $1.3 million, or 12%, to $12.6 million from $11.3 million for the three months ended December 31, 2022
View on SEC.gov

Browse all earnings releases →

PRO DEX INC filing history →

Source: SEC EDGAR
accession 0001079973-24-000182
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.